{"name":"Arcellx, Inc.","slug":"arcellx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":22286000,"revenueGrowth":-79.4,"grossMargin":0,"rdSpend":157611000,"netIncome":-228934000,"cash":80262000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ARC-T Cells","genericName":"ARC-T Cells","slug":"arc-t-cells","indication":"Other","status":"phase_1"},{"name":"SPRX002","genericName":"SPRX002","slug":"sprx002","indication":"Other","status":"phase_1"},{"name":"anito-cel","genericName":"anito-cel","slug":"anito-cel","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARC-T Cells","genericName":"ARC-T Cells","slug":"arc-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SPRX002","genericName":"SPRX002","slug":"sprx002","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"anito-cel","genericName":"anito-cel","slug":"anito-cel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQTy1raGJrS3hYSlNoN1p5MVNvN2FoZklBek5TMmUyS3kzd2RJSU9ZcWFiS0hmdG5WekdjcEhYTnZHMDRiZHNZYW9DOUZrMGJlUzZuLXQxZXNyamI3enBDbGxHTXp2VkVBd0NfcGluSXVreG8yZWJ6ekVidmFNdGpMRWhENzVINUd4WW1mRF9HYjlOenhkUURwNlpOempjbV81MzVzZkRJUFBkUXlTZ3BjTEYxTjNMNmd5V3BFY0hDR3R0cHhjOXBqU2hsVQ?oc=5","date":"2026-03-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology","headline":"Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVmdubTJOVGgxSnNweVRYM041cmM5NWNUdWhFdU85VTVtcV82amV6WTNLSGtMT2pVZHQzb1R5RlVzNUEzMk5GcHdCZ1FVN1hndXNwRVlya0VMREhhZUR3YUhpUklEbk51WnVmaFEwbDh4YUd0ZkpvRmNUYWRMcUNSQ0N5YjBuaFJwQ1FDbU4zZw?oc=5","date":"2026-03-10","type":"deal","source":"Finviz","summary":"Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Finviz","headline":"Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQemc0M09ENXpYSHVienBIMVJwRldUMk1USnkwNjlOMW56VVk4U1JBMkF2cTJUODZmd3dLbG5jdl9vOEVTMlFheDNFdjdHUHoyQ1Vzd2NGR2xVazc1WVhCTC1wc2tub2tsUnhGM3dhckRHeVE5R2tidXdqRDZHV0dtS2pLUDZhMzRZSHpvMUluWFcxcFNicTdXWHdjaW9iUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"European Pharmaceutical Review","summary":"Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx - European Pharmaceutical Review","headline":"Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbnZxcmhlTVcxTUQ1UU5jNEpnX3hGX0RIcjk1S3Q2WDRUU1UxbTMyODJCZ0NWWlI2WDVSSGVtelJFNHJ5cnF1Y3o1ZVByOUpxYjVWQTZoWE5ZT19GalpIT0RwTzVpYWNYN29Bcy12eVlmZTJQN1VYSXZIREl2NldRdGN6YUtYb0NCZktwbmhlZHZOTGJJem1Sc2VoX21hS0hqWkJHV1RKSlQ?oc=5","date":"2026-02-23","type":"deal","source":"BioPharma Dive","summary":"Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive","headline":"Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNeHFKZnB0ZURwWWhDam9ndFJiMmVLRkJFeGRyQnBycUFjOXFSc0toS1FSbWN2eXc4YkxwamJ1eUFNTkh1VGRNOC1LUWRZenhCT1NfMkZNMXJyZWlfbmxROURpSUNnTFdlSWs2MVZGeG5tRjFuQUNxSC1ORTducE9UMV9CQlRlRWU2UnozX2NGZC3SAZYBQVVfeXFMTnZqWDdTa0pQR0JXSnVLdzdiU2ZPRWRjOTRGRVJOOS1UVk0yRTl6Q1Z4Q1Q5VVRwUDhDWnVfQTNPak5JUk4zb3lQMHp5WXMxemVNNUljRDhKUzlucEl1RFd0dzdTeUEtUEdCWmdQZzZnQ01rbUJ0SEVpaGNWU0x2ZDRlS2lpZnNsdTh4Q1NRSm12MDhtNnF3?oc=5","date":"2026-02-23","type":"deal","source":"CNBC","summary":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion - CNBC","headline":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNYUUyZVhTZ0NZekVxc0VlMjEwLUpPenUxcHZqRVlZczliNVV6cWpTc3M3V0E1UlQwblp6bmpIdU5TOUZjakNlZTVZYjdOV3pCaDhVVG1zeHBHcmJhRjdrTVUzRnNjXzVhcnZweHlvaG1tYzZrOUVYLUZxeXgzRmdNaw?oc=5","date":"2026-02-23","type":"deal","source":"Barron's","summary":"This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's","headline":"This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMXJab09HTkI3Z251V0pEOC1TX0piWkNkNXhXXzVTZkVVV0NTN0lFZ2gtZHVDOEFocHJqREFSZE1IcWxIWVRyVEItRGNGUTh2WnRwYzVEcnJqZ3VtazdSUjdQV2gyb25nUFg0RmlYRWI3UXp4OGptcnI0aERuUURuUDFEaXFnazdHenR4QTZjYmxsSl9wTWc?oc=5","date":"2026-02-23","type":"pipeline","source":"BioWorld News","summary":"Gilead brings Arcellx fully under the fold for $7.8B - BioWorld News","headline":"Gilead brings Arcellx fully under the fold for $7.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNU0dTYnliaW9YYUgzMHdNRHZHRTdSQkJBMkJrUjh0eFZRbjNscmhCWllDT3ZELW50UE5kOFoyVGNiR0I4S3h5Z3lNYU93ZU5WaURlbVFQUzNUSmt4V3F1c3VNbW11YmxELXZYQW9wcVZib19HZWMwWkNabEFOcHQtcDV2RlIxeVlFb0ZaVmZVMkhmalE?oc=5","date":"2026-02-23","type":"deal","source":"Reuters","summary":"Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters","headline":"Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNb2J3ZHFQSUVaM3BkX29LR3RicTVGYzhqWVRoSmxTNjl3Z2dLazZFQmVpd2VJTnBkZ28wZ0tza2o0SDd0UnRTS0FFSld1dXUzdGU5bzJOTC04LXNZajFFbWN1OUlFRjlzOHFrLXVQcUZuQXk3cU1CeVdpaUU0X3dDVm9uakU?oc=5","date":"2026-02-23","type":"deal","source":"Contract Pharma","summary":"Gilead Sciences Acquires Arcellx - Contract Pharma","headline":"Gilead Sciences Acquires Arcellx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNeGxCQ1ZiQ0tTd25PU3BFcUlJbmVGUzFzWFJ3S1ZGQzU5NkpaeXhjM0FHdEc2YVRpVlozTVB2MzFxUUl2Z015b3RkdEh6dVhFWmstMVVPQVgwVV9Wdll3WnhIYm5TQjlJVnVZR1VLWGJTUVN0Y0xmNzVkWW5uWWx3Um1qU0k0d1RTaFNqSV9xclVzMjg?oc=5","date":"2026-02-23","type":"pipeline","source":"BioSpace","summary":"Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace","headline":"Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbDZjWFd3WHljZjJNZjBBYWJWNGVWREtpLTg0ZzNuM2V6VkFiX3U3clRfaE9RdzdRa0h2eHY4ZWVpNDRDcDVVNV9OQkxZOTZ4NDcwZUQtUXFhaFlXWXhvUGd0RFByYkkzVHRtRndMai1VbUJXOE1rWm9McC1XS2lqVnBNRW8yTVZwRDJyZWlOZnItUG5tMlVsOXRWLU9iNW8?oc=5","date":"2026-02-23","type":"deal","source":"Pharmaceutical Technology","summary":"Gilead acquires CAR-T specialist Arcellx for $7.8bn - Pharmaceutical Technology","headline":"Gilead acquires CAR-T specialist Arcellx for $7.8bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQY25CRllUR3pseUdIV3I0ZEtPajVTd1RwNFBsLTlKZlROdUJ6RkNwMmlYWDBST3d1b0dOaWpVTXU0S1A2bXYxWFZicXVWSTA4V0RITHNPdkFvY0ZYZFJWSU05VDhVaUxkcDFmSmdzeWJIak43UjVKRk96dVBxRW92SkVhUzFBOXNJa3I2TWdtaUxwZ3VpMzR1Rmh2YUdUcTFjWGxsT0QtYWMwa3NNTEtMNWtCYlhjLUlTT2lGVndxYXl6UXFyZzI3R2NDM3JYU1BSemo0Mm11REIydHd3TW51OFZZX3QtTUlOS1RkNkZwOWRRU1ZtWkY3SGdRc1drUQ?oc=5","date":"2026-02-23","type":"earnings","source":"Sahm","summary":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Sahm","headline":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday","sentiment":"positive"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":22286000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":22286000,"period":"2025-12-31"},{"value":107936000,"period":"2024-12-31"},{"value":110319000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":157611000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-228934000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":80262000,"cashHistory":[],"totalAssets":603990000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}